Evolution of liver stiffness and post-treatment surveillance by liver elastography for HCV patients in the DAA era

Piecha, Felix; Gänßler, Jan-Michael; Ozga, Ann‐Kathrin; Wehmeyer, Malte H.; Kluwe, Johannes; Lampalzer, Sibylle; Creutzfeldt, Anna; Buescher, Gustav; Horvatits, Thomas; Sterneck, Martina; Pischke, Sven; Lohse, Ansgar W.; Wiesch, Julian Schulze zur

doi:10.1080/00365521.2021.1915374

Cited by 4 publications

(2 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In their study, the mean TE values were 26.4 ± 11.7 KPa with a decrease to 23.5 ± 13.3 KPa ( p = 0.01); approximately 59.2 % of the patients exhibited a decrease of more than 10 % in KPa values; 24.1 % had stable values; and 16.4 % experienced an increase in KPa values between pretreatment and posttreatment with DAAs. Additionally, in the study by Piecha et al, 27 which evaluated 346 patients before and after treatment, 77 % of the patients had a KPa reduction of more than 10 %, 14 % had a reduction of up to 10 %, and 10 % had an increase in KPa greater than 10 %. These variations in responses among patients post-SVR with treatment align with the observation that while there is a decrease in the risk of decompensation and/or HCC following treatment, the risk is not entirely eliminated.…”

Section: Discussionmentioning

confidence: 98%

Noninvasive assessment of liver fibrosis can predict clinical outcomes at late follow-up after a sustained virological response in HCV patients?

Ragazzo,

Zitelli,

Mazo

et al. 2024

Clinics

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 98%

Noninvasive assessment of liver fibrosis can predict clinical outcomes at late follow-up after a sustained virological response in HCV patients?

Ragazzo,

Zitelli,

Mazo

et al. 2024

Clinics

View full text Add to dashboard Cite

“…However, patients with HCV infection undergoing successful antiviral treatment display an improvement in liver function due to the alleviation of HCV-driven intrahepatic inflammation [ 3 ]. In fact, the eradication of HCV is associated with significant improvements in liver stiffness (LS), which is among the most accurate non-invasive tools to assess the fibrosis stage [ 4 , 5 , 6 ]. This is clear even when considering the onset of portal hypertension, which is responsible for overt decompensation [ 7 ].…”

Section: Introductionmentioning

confidence: 99%

Changes in Liver Stiffness and Markers of Liver Synthesis and Portal Hypertension following Hepatitis C Virus Eradication in Cirrhotic Individuals

Armandi

Rosso

Troshina

et al. 2022

Biology

View full text Add to dashboard Cite

The advent of direct antiviral agents (DAAs) has radically changed the natural history of hepatitis C virus (HCV) chronic liver disease. Even patients with cirrhosis may display improvements in liver function or features of portal hypertension following viral eradication. The aim of this study was to assess whether a HCV cure would lead to improvements in cirrhotic patients using simple, readily available tools in clinical practice, together with liver stiffness (LS) measurement. This is a retrospective study of cirrhotic patients with cured HCV infection, with or without previous decompensation. Clinical and biochemical parameters as well as LS measurements were collected before antiviral treatment with DAAs and after 6 months following sustained virological response. Hepatic synthesis was assessed by serum albumin levels. Portal hypertension was indirectly assessed by platelet count. Liver function was determined by the CHILD score. A total of 373 cirrhotic patients with successful HCV eradication were retrospectively included. After 6 months of follow-up, a significantly higher proportion of patients showed improved liver function, shifting from the CHILD B/C to CHILD A group, (71.4%, p < 0.001). Similarly, LS improved from a median of 19.3 kPa (14.7–27) at the baseline vs. a median of 11.6 (7.7–16.8 kPa) at follow-up (p < 0.001). The proportion of patients who showed improved hepatic synthesis was 66.0%, which was statistically different when compared to that of patients who had a worsened condition (0.3%) (p < 0.001). Moreover, when classifying the cohort according to the RESIST-HCV score, we found that a significant proportion of patients shifted into the “low risk” group following DAA treatment (52% baseline vs. 45.6% at follow-up, p = 0.004). Even in the decompensated patients, LS improved from 1.6 to 2-fold from the baseline. Antiviral treatment is effective in improving indirect signs of hepatic synthesis and portal hypertension. Similarly, the LS values displayed significant improvements, even in decompensated patients.

show abstract

Hepatitis Viruses: Hepatocellular Carcinoma

Lee,

Yang,

Chaiteerakij

et al. 2023

Viral Infections of Humans

View full text Add to dashboard Cite

Evolution of liver stiffness and post-treatment surveillance by liver elastography for HCV patients in the DAA era

Cited by 4 publications

References 36 publications

Noninvasive assessment of liver fibrosis can predict clinical outcomes at late follow-up after a sustained virological response in HCV patients?

Noninvasive assessment of liver fibrosis can predict clinical outcomes at late follow-up after a sustained virological response in HCV patients?

Changes in Liver Stiffness and Markers of Liver Synthesis and Portal Hypertension following Hepatitis C Virus Eradication in Cirrhotic Individuals

Hepatitis Viruses: Hepatocellular Carcinoma

Contact Info

Product

Resources

About